Navigation Links
Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
Date:12/31/2008

Corifollitropin alfa, a sustained follicle stimulant, extends options for patients and Schering-Plough's leadership in fertility

KENILWORTH, N.J., Dec. 31 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP), a leading provider of fertility treatments, announced today that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS). This application will follow the Centralized Procedure.

Corifollitropin alfa is being developed as a potential treatment in Controlled Ovarian Stimulation (COS) for the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology (ART) program. Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as (recombinant)Follicle Stimulating Hormone (FSH), but with a markedly prolonged duration of FSH activity. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of corifollitropin alfa may replace the first seven injections of (recombinant)FSH preparation in a COS treatment cycle.

If approved, corifollitropin alfa would extend Schering-Plough's leading fertility portfolio, which also includes PUREGON(R).

Corifollitropin alfa Important Safety Information

The most frequently reported adverse drug reactions during treatment with corifollitropin alfa in clinical trials are Ovarian Hyperstimulation Syndrome (OHSS), pelvic pain and discomfort, headache, nausea, fatigue and breast complaints (including tenderness). They are reported with an incidence between 1% and 6%.

PUREGON(R) Important Safety Information

<
'/>"/>
SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Anitha Nallari, MD has joined Shakir ... in Columbus, OH. Dr. Nallari will see patients with ... breast cancer, lung cancer, GI and gallbladder cancer, head and ... hematology. , Dr. Anitha Nallari is Board Certified ... Board of Internal Medicine. She completed her medical education in ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
(Date:5/6/2015)... The 2015 STEMtech conference exhibition hall ... booth selection . Don’t miss this opportunity to ... and university decision-makers from around the country. , This ... the Arizona Grand in Phoenix. This beautiful all-suite hotel ... doorstep of the South Mountain Preserve. The Phoenix area ...
(Date:5/6/2015)... Los Angeles, California (PRWEB) May 06, 2015 ... has secured its first round of VC funding and ... , The enterprise class embeddable software enables applications ... transform data as it moves between systems and locations. ... the HyperTransfer technology moves files at line speed, independent ...
(Date:5/6/2015)... New york, NY (PRWEB) May 06, 2015 ... on strategy, design, creative and technology, announced today that ... an expert advisor by Shocase, a marketing professional network ... the marketing sector. , Widely regarded as a specialist ... of the most high-profile branding programs over the last ...
Breaking Medicine News(10 mins):Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:STEMtech Conference Exhibitors Gain Access to Community College and University Representatives From Across the U.S. 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4Health News:Shocase Selects MBLM’s Claude Salzberger as Company Advisor 2
... survival of cells that are exposed to stress. Researchers at ... operation some time ago but now Hsp90 has surprised ... results are published in the current online issue of the ... cancer medication. Proteins are the motors of the cell: ...
... Playing "media detective" allows children to understand the intentions of ... resist messages that encourage alcohol or tobacco use. ... shows that teaching children as early as third grade to ... use. The study, based on the research of Erica Weintraub ...
... Steven Reinberg HealthDay Reporter , MONDAY, Aug. 23 ... potentially tainted by salmonella, the head of the U.S. Food ... additional sort of sub-recalls over the next couple of days, ... distribution of these eggs that are contaminated," agency director Margaret ...
... at math in school, so that,s what she pursued as a ... Houston, Texas, and met some cardiologists at a party, she started ... them. "I realized we could provide them with a fluid ... about, for example, which stent grafts they use in their procedures," ...
... flooding of New Orleans caused the evacuation of 1.5 ... remained displaced, many residing in highly transitional shelters, including ... mark, substantial consequences from this prolonged displacement have resulted ... the region, according to a new study by the ...
... Although the medical community has already accepted that colorectal ... researchers have found that computed tomography colonography (CTC or ... the yield of identifying significant early extracolonic (outside the ... study in the September issue of the American Journal ...
Cached Medicine News:Health News:Munich researchers demonstrate rocking movement in the anti-stress protein Hsp90 2Health News:'Media detective' tool empowers children to skirt alcohol and tobacco marketing messages 2Health News:FDA Chief Says More Egg Recalls Possible 2Health News:FDA Chief Says More Egg Recalls Possible 3Health News:FDA Chief Says More Egg Recalls Possible 4Health News:Math from the heart: Simulating stent design and coating 2Health News:Math from the heart: Simulating stent design and coating 3Health News:'Legacy of Katrina' report details impact of stalled recovery on mental health status of children 2Health News:'Legacy of Katrina' report details impact of stalled recovery on mental health status of children 3Health News:'Legacy of Katrina' report details impact of stalled recovery on mental health status of children 4
(Date:5/6/2015)... Mass., May 6, 2015 NxStage Medical, Inc. (Nasdaq: ... products, today reported first quarter financial results that exceed ... Revenue for the first quarter of 2015 increased ... $72.2 million for the first quarter of 2014. The ... $77.5 million to $78.5 million.  The increase was driven ...
(Date:5/6/2015)... 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... that it will host a conference call and webcast ... the period ended March 31, 2015 and to provide ... clinical program for aramchol. Conference Call ...
(Date:5/6/2015)... 6, 2015   Sigma-Aldrich Corporation (NASDAQ: SIAL ... today announced a $50,000 product donation to the ... replicate key findings from recent high-impact papers in the ... between the online research marketplace Science Exchange , ... the open-access journal eLife. The goal of ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 2Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 3Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3
... the American,Society of Hematology (ASH) and the American ... joint guideline on the use of,erythropoiesis-stimulating agents (ESAs), ... to produce more red blood cells, to treat,chemotherapy-related ... to inform clinicians with the most,up-to-date evidence from ...
... and efficacy of TAXUS drug- ... stent compared to bare-metal stent, NATICK, Mass., and WASHINGTON, ... announced five-year and final,follow- up data from its TAXUS IV ... -- in patients who received a TAXUS(R),Express(TM) Paclitaxel-Eluting Coronary Stent ...
Cached Medicine Technology:ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 2ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 3Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 2Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 3Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial 4
... The Uniflex Humeral Nail System has been ... in which noninvasive treatments have historically failed ... a unique blend of strength and flexibility. ... strength of titanium alloy is twice that ...
... Building on a strong heritage, the ... a new standard in ophthalmic ultrasound instrumentation. ... options, OcuScan RxP makes it simple to ... reproducible. Designed to enhance patient care by ...
... The AIM Titanium Tibial ... address the mechanical failures of ... indications for tibial interlocking nails. ... full range of diameters and ...
Arthroscopic instrument system for instability and SLAP fixation....
Medicine Products: